Back

Utility of mineralocorticoid receptor antagonists in reducing burden of atrial fibrillation

European Heart Journal

17 October 2024
Organised by: Logo
Read full article
ESC Journals ARRHYTHMIAS AND DEVICE THERAPY CARDIOVASCULAR PHARMACOLOGY Atrial Fibrillation (AF) PREVENTIVE CARDIOLOGY Risk Factors and Prevention

Contributors

Thalys Sampaio Rodrigues
Thalys Sampaio Rodrigues

Author

Prashanthan Sanders
Prashanthan Sanders

Author

University of Adelaide Adelaide , Australia

Han S Lim
Han S Lim

Author

Austin and Northern Health, University of Melbourne Melbourne , Australia

You may be interested in
thumbnail
Webinar
Nonsteroidal MRAs and heart failure: interpretation and impact on practice - which patients should be receiving MRAs?
21 July 2025
thumbnail
Congress Presentation
Inflammation and arterial hypertension are the main risk factors occurrence of AF in patients with heart failure patients with preserved ejection fraction (retrospective study)
12 May 2024
thumbnail
Congress Session
How to improve outcome of patients with atrial fibrillation?
1 April 2025
thumbnail
Congress Presentation
The non-steroidal mineralocorticoid receptor antagonist finerenone prevents structural cardiac remodeling
3 September 2019

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources